Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-08-18), Genmab AS's 3-1 Month Momentum % is 9.41%.
The industry rank for Genmab AS's 3-1 Month Momentum % or its related term are showing as below:
CHIX:GMABc's 3-1 Month Momentum % is ranked better than 77.72% of 1387
companies
in the Biotechnology industry
Industry Median: -7.61
vs CHIX:GMABc: 9.41
Genmab AS (CHIX:GMABc) 3-1 Month Momentum % Explanation
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Genmab AS 3-1 Month Momentum % Related Terms
CHIX:GMABC vs VRTX, REGN, RVMD: 3-1 Month Momentum % Comparison
For the Biotechnology subindustry, Genmab AS's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genmab AS 3-1 Month Momentum % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Genmab AS's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Genmab AS's 3-1 Month Momentum % falls into.
Genmab AS (CHIX:GMABc) 3-1 Month Momentum % Calculation
3-1 Month Momentum % is calculated as following:
3-1 Month Momentum %
=
( Price 1-month ago
/
Price 3-month ago
- 1 )
*
100 %
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Genmab AS (CHIX:GMABC) has a 3-1 Month Momentum % of 9.41% as of Aug. 18, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Genmab AS and its competitors. According to the industry distribution chart, Genmab AS ranks #309 out of 1387 companies in the Biotechnology industry, placing it in the top 22.3%.
Is Genmab AS's 3-1 Month Momentum % too high?
Genmab AS's current 3-1 Month Momentum % is 9.41%. Based on the distribution chart, Genmab AS ranks #309 out of 1387 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Genmab AS has a GF Score™ of 97/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Genmab AS's 3-1 Month Momentum % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Genmab AS ranks #309 out of 1387 companies for 3-1 Month Momentum %. This places Genmab AS in the top 22% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Biotechnology company?
A good 3-1 Month Momentum % depends on the Biotechnology industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Genmab AS and its competitors. Genmab AS's current 3-1 Month Momentum % is 9.41%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genmab AS stock overvalued right now?
Based on GuruFocus' analysis, Genmab AS (CHIX:GMABC) is currently considered Fairly Valued. The stock's GF Value™ is kr2,299.97, compared to a current price of kr2,108.00 — trading 8.3% below its estimated fair value. The current 3-1 Month Momentum % is 9.41%. Genmab AS's overall GF Score™ is 97/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Genmab AS (CHIX:GMABC), the current 3-1 Month Momentum % is 9.41% as of Aug. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Genmab AS (CHIX:GMABC) Overvalued in 2026?
Based on GuruFocus' analysis, Genmab AS stock appears to be undervalued.
The current stock price of kr2,108.00 is trading 8.3% below its estimated GF Value™ of kr2,299.97.
GuruFocus considers Genmab AS to be Fairly Valued.
Key valuation signals for CHIX:GMABC:
3-1 Month Momentum %: 9.41%
GF Value™: kr2,299.97 vs. price of kr2,108.00 (8.3% below fair value)
No single metric tells the full story. See the CHIX:GMABC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
97GF Score
Get the complete analysis for CHIX:GMABC
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:GMABC has been successfully added to your 
